

Human IGF-II R Fluorescein-conjugated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: FAB2447F 100 TESTS


DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human IGF-II R in direct ELISAs and Western blots.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human IGF-II R Ser1510-Phe2108 Accession # P11717		
Conjugate	Fluorescein Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm		
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.		
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	10 μL/10 ⁶ cells	See Below

DATA



Detection of IGF-II R in Human Blood Monocytes by Flow Cytometry. Human peripheral blood monocytes were stained with Goat Anti-Human IGF-II R Fluoresceinconjugated Antigen Affinity-purified Polyclonal Antibody (Catalog # FAB2447F, filled histogram) or isotype control antibody (Catalog # IC108F, open histogram). View our protocol for Staining Membraneassociated Proteins.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.

• 12 months from date of receipt, 2 to 8 °C as supplied.





Human IGF-II R Fluorescein-conjugated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: FAB2447F

100 TESTS

BACKGROUND

The type 2 Insulin-like Growth Factor Receptor (IGF-II R; also known as cation-independent mannose-6 phosphate receptor/CI-MPR) is a 300 kDa member of the P-type lectin family of molecules. P-type lectins generate functional eukaryotic lysosomes by binding and sorting lysosomal enzymes expressing phosphorylated mannose residues (M6P) (1-3). IGF-II R is a type I transmembrane glycoprotein that contains a 2,264 amino acid (aa) extracellular region, a 23 aa transmembrane segment and a 124 aa cytoplasmic tail (4, 5). The extracellular region consists of 15 contiguous "binding" repeats of about 150 aa each. The odd-numbered repeats interact with "ligands" while the even-numbered repeats likely generate a nondisulfide homodimer in the membrane (1). Repeat #11 binds IGF-II, while repeats 3 and 9 bind mannose-6 phosphate; repeat #13 contains a fibronectin type II motif and assists in IGF-II binding (1, 2). In the extracellular region of IGF-II R expressed by R&D Systems (600 amino acids), human IGF-II R is 85% identical to both mouse and bovine IGF-II R. This expressed region includes binding repeats #11, 12, and 13. In addition to IGF-II, CI-MPR/IGF-II R binds non-M6P containing ligands such as retinoic acid, urokinase-type plasminogen-activator receptor and plasminogen, plus M6P-containing molecules such as lysosomal enzymes, TGF-β1 precursor, proliferin, LIF, CD26, herpes simplex glycoprotein D, and granzymes A and B (2, 6). IGF-II R regulates many diverse biological functions that range from intracellular trafficking to the internalization of extracellular factors and modulation of cellular responses. It delivers newly synthesized M6P-tagged lysosomal enzymes from the trans-golgi network to endosomes, and facilitates the clearance of extracellular lysosomal and matrix degrading enzymes by internalization into clathrin-coated vesicles and delivery into endosomes. With respect to IGF-II biology, it would appear that IGF-II R is principally a regulator of local IGF-II levels, targeting IGF-II for destruction in lysos

References:

- 1. Ghosh, P. et al. (2003) Nat. Rev. Mol. Cell. Biol. 4:202.
- 2. Dahms, N.M. and M.K. Hancock (2002) Biochim. Biophys. Acta. 1572:317.
- 3. Zaina, S. and J. Nilsson (2003) Curr. Opin. Lipidol. 14:483.
- Morgan, D.O. et al. (1987) Nature 329:301.
- 5. Oshima, A. et al. (1988) J. Biol. Chem. 263:2553.
- 6. Hawkes, C. and S. Kar (2004) Brain Res. Rev. 44:117.

